Interesting piece from a Brussels thinktank on the EU vaccination program. I have never heard of Breugel before, no idea where they sit on any ideological issue dimensions.
I’m sure I’ve heard of Bruegel before but can’t exactly remember when or where from. I have a feeling it was in the economist many years ago, either a reference to them or a job placement at the back of the magazine (I haven’t read it for a number of years)
You did infere it whether you intended to or not, it’s all in one sentence. When I tried to clarify that you did not acknowledge that.
It doesn’t matter if you used the word recombination or not by talking about Sanofi’s statement in Q4 about phase 1 and 2 trials you where talking about the recombination technology (which I pointed out later). I also pointed out that the flexibility of the recombination technology meant that the vaccine path was far from a none starter and should even be persued with vigor. As Sanofi’s statement indicated they had identified the problem and had a solution.
Have AZ specified a reason for not hitting production targets of their vaccine.
1 Like
They’ve said that the EU based plants have so far produced a smaller yield. Like growing a culture. It’s an imprecise science apparently and happens quite often. They’re trying to work out the issues. They’ve also hinted at other logistical issues but I’m not sure on the details.
1 Like
The reason I ask is last year there was I think a shortage of reagent used in testing for covid. Could the slowdown in production of the AZ vaccine be a supply of some ingredient in the manufacture of the product.
1 Like
1 Like
2 Likes
All four of us in our house have covid, me, wife, two teenage kids. I have been tired and achy, lost smell and taste. Turned a bit of corner and today felt much better than yesterday. Quarantine period ends Tuesday, assuming no temp.
Could be a lot worse.
11 Likes
Get well soon mate.
11 Likes
I think we have gone over our differences enough now so will come back to this.
1stly Sanofi and the French government has said from the start they are willing (and the government actively wants French involvement in the covid response)… It is said the goverment has actively been pushing Sanofi to get involved.
Apparently Pfizer has conditionning limits at it’s plant in Mayenne (sp?) and Sanofi has ability to provide extra conditionning at their Francfort plant (which wouldn’t have anything to do with their internal covid response anyway) The fact that it’s going to take 6 months to get up to capacity indicates that that time is for Pfizer to increase vaccine output. More importantly the conditioning of a product that is stored at liquis nitogen temperatures can not be easy and Sanofi must be making some drastic changes to some area on what is an enormous plant. Which inturn indicates some large investment that at a guess is being shared.
So Pfizer has the capacity to increase production and Sanofi is offering a ‘cheap’ way to condition the product all over a 6 month period before beingput in place. Seems reasonable if true.
2 Likes
How is he; has he had any side affects? I had my first jab two days ago - didn’t feel a thing (brilliant nurse) and no adverse symptoms. 
3 Likes
Conveyor belt, he was in and out in 5 mins, didn’t feel it and no effects whatsoever. Very well organised.
4 Likes
Sounds like a similar experience to mine. Very efficient.
Pity they’re cutting back supplies to the Northwest.
2 Likes
1 Like
If this article is correct (given the paper) then levelling up the whole country having gone hard with us first makes sense.
Does anyone have any idea why the BAME population of the UK is four times more likely (than the general population) to die from a Covid infection, when India, for example, has a much lower death rate (111 deaths per million) than the UK as a whole (1,496 deaths per million).
Is it, as I suspect, a function of the fact that India is doing proportionally far fewer tests, and that Covid deaths are simply slipping under the radar?
1 Like
I know people are dying and the whole situation is horrific. But I can’t help think we should have held off the final BREXIT deal for a month. This is meant in jest before anybody jumps up and down.
Is the disparity due to certain areas e.g. Northeast & Northwest, having set up more efficient vaccination services, or that they have just been given more doses?
If it is the latter, then it makes sense to divert it (the vaccine) to the areas with the highest number of
at risk patients awaiting vaccination.
If it is the former, then it is simply penalising the better organised regions. Will the less well organised regions receiving the diverted vaccines be capable of utilising the doses, or will there be wastage?